Sensitive procedure for the determination of reboxetine enantiomers in human plasma by reversed-phase high-performance liquid chromatography with fluorimetric detection after chiral derivatization with (+)-1-(9-fluorenyl)ethyl chloroformate.
A sensitive and selective high-performance liquid chromatographic method for the determination of reboxetine enantiomers in human plasma was developed. Although two chiral centres are present in reboxetine, its stereospecific synthesis leads to two rather than four possible enantiomers. After extraction from plasma and reaction with (+)-1-(9-fluorenyl)ethyl chloroformate, reboxetine enantiomers were separated as diastereoisomeric derivatives by reversed-phase high-performance liquid chromatography (HPLC) and determined by fluorimetric detection. The HPLC analysis time was about 90 min. The linearity, precision, accuracy and limit of quantification of the method were evaluated. No interference from blank plasma sample was observed. The suitability of the method for in vivo samples was assessed by the analysis of plasma samples obtained from a healthy male volunteer who had received a single oral dose of 4 mg of reboxetine in tablet form.
Frigerio
E
E
Farmitalia Carlo Erba, Pharmacokinetics and Metabolism Department, Milan, Italy.
Pianezzola
E
E
Strolin Benedetti
M
M
D000928:Antidepressive Agents / Q000097:blood* / Q000737:chemistry; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D005069:Evaluation Studies as Topic; D005449:Fluorenes; D006801:Humans; D007202:Indicators and Reagents; D008297:Male; D009025:Morpholines / Q000097:blood* / Q000737:chemistry; D000077593:Reboxetine; D013050:Spectrometry, Fluorescence; D013237:Stereoisomerism
D000928:Antidepressive Agents; D005449:Fluorenes; D007202:Indicators and Reagents; D009025:Morpholines; C052812:1-(9-fluorenyl)ethyl chloroformate; D000077593:Reboxetine